AHA: After 2007 Recs, Increase Seen in Infective Endocarditis
TUESDAY, Nov. 6, 2018 -- Following the 2007 American Heart Association (AHA) update of recommendations for antibiotic prophylaxis (AP) to prevent infective endocarditis (IE), there has been a decrease in AP and an increase in IE incidence for high-risk individuals, according to a study published online Nov. 5 in the Journal of the American College of Cardiology. The research was published to coincide with the annual meeting of the American Heart Association, held from Nov. 10 to 12 in Chicago.
Martin H. Thornhill, M.B.B.S., Ph.D., from the University of Sheffield in the United Kingdom, and colleagues examined any change in AP prescribing and IE incidence using data for high-, moderate-, and unknown/low-risk individuals with linked prescription and Medicare or commercial health care data (198,522,665 enrollee-years of data).
The researchers found that the 2007 recommendation change was associated with a significant 64 percent estimated decrease in AP prescribing for moderate-risk individuals and a 20 percent estimated decrease for high-risk individuals by August 2015. During the same period, there was a barely significant 75 percent estimated increase and a significant 177 percent increase in IE incidence among those at moderate and high risk, respectively. A significant 52 percent decrease was seen in AP prescribing among unknown/low-risk individuals, but there was no significant increase in IE incidence.
"Although the data do not prove a cause-effect relationship between AP reduction and IE increase, they are very supportive of the AHA recommendation to give AP to those at high risk but not to those at moderate risk of endocarditis," Thornhill said in a statement.
© 2020 HealthDay. All rights reserved.
Posted: November 2018
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.